A new pharma dawn beckons as Pfizer buys Wyeth for $68 billion - update
This article was originally published in Scrip
Executive Summary
Pfizer's agreed acquisition of US rival Wyethfor $68 billion will be the industry's biggest deal for nearly a decade. But the agreement designed to soften the upcoming loss of Lipitor (atorvastatin) to generic competition will herald tens of thousands of job cuts, and raised speculation of a new wave of consolidation within the industry.